Cyclerion Therapeutics Merges With Korsana Biosciences to Advance Alzheimer’s Drug Development

Cyclerion Therapeutics (CYCN) has merged with Korsana Biosciences to form a new entity named Korsana Biosciences, trading under the ticker KRSA. The merger aims to advance Korsana’s Alzheimer’s drug pipeline, including KRSA-028, and is supported by $380 million in private financing. The combined entity plans to reach key clinical milestones by 2027.

By Maham Fatima Mon, April 20, 2026 at 5:15 PM GMT+3 2 min read · Yahoo Finance · April 20, 2026, 14:15 UTC

Tickers: $CYCN

Topics: Alzheimer's Disease Biotech Clinical Trials Funding Mergers & Acquisitions

Read the full article at Yahoo Finance

More World news

The Adecco Group Reports Q3 2026 Growth Driven by Temporary Staffing and Margin Expansion PR Newswire · November 12, 2026, 18:54 UTC
Twist Bioscience Projects FY2027 Revenue Between $550M and $560M Seeking Alpha · November 12, 2026, 18:50 UTC
Dixie Group Reports Q3 Sales Growth Amid Margin Pressure and Future Cost-Reduction Targets Seeking Alpha · November 12, 2026, 18:50 UTC
Data I/O Corporation Targets Rapid V-TEK Synergy Realization Amid $80 Million M&A Pipeline Seeking Alpha · November 12, 2026, 18:50 UTC
Leatt Corporation Reports 43% Increase in Q3 Revenue to $20.46 Million Seeking Alpha · November 12, 2026, 18:50 UTC
Parsons Reports Strong Third Quarter Results Driven by High-Margin Product Shift Motley Fool · November 12, 2026, 18:45 UTC
C.H. Robinson Reports Q3 2026 Earnings Driven by AI Efficiency and Margin Expansion Motley Fool · November 12, 2026, 18:45 UTC
Baker Hughes Raises Guidance Amid Surging Data Center Power Demand Motley Fool · November 12, 2026, 18:45 UTC
California Supreme Court to Rule on Insurance Overcharge Liability Under Proposition 103 PR Newswire · November 12, 2026, 18:44 UTC
Federal Court Orders Veterans Guardian to Pay Treble Damages to Disabled Veteran Class PR Newswire · November 12, 2026, 18:41 UTC